🟢 Rezolute is trading 5% up with no clear catalyst identified

Rezolute is trading 5.26% higher at $4.11, but no confirmed catalyst has been identified for the advance.

• No company-specific announcement dated September 28 clearly explains the rise; trading-volume details were not provided.
• Broader markets are lower, so Rezolute is moving against the trend. The latest update says FDA review of sunRIZE data continues and topline tumor HI upLIFT results are expected before year-end; these are prior updates, not a confirmed session catalyst.